$GEHC

GE HealthCare (GEHC) exec has stock withheld at $71.23 for taxes

GE HealthCare Technologies (GEHC) reported that CEO Jeannette Bankes had 1,064 shares withheld on September 1, 2026, to cover taxes on vested restricted stock units. The shares were valued at $71.23 each, totaling $76K. Bankes holds 37,293 shares directly after the transaction.

Original reporting
Published Sep 3, 2026, 8:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 12:08 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$GEHC
Neutral
high confidence
Mentioned
$GEHC
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$GEHCNeutralLow
01

Why it matters

Routine tax‑withholding transaction; unlikely to move the stock.

02

Market read

Minor insider filing with limited trading relevance.

03

What to watch

Potential future insider activity if additional RSU vestings occur, but no immediate relevance.

Relevance 4/10Novelty 4/10Timing: post‑transaction (Sep 1 2026 filing reported Sep 3)

Background

Form 4 filings are required disclosures of insider transactions. Tax withholding of RSU shares is a standard practice.

Company-level read

Ticker impact

$GEHCNeutralHigh confidence
Context

Form 4 disclosed that CEO Jeannette Bankes had 1,064 shares withheld on Sep 1, 2026 to cover tax on vested RSUs, leaving 37,293 shares held.

Expected impact

Minimal effect; likely no immediate price movement.

Evidence & confidence

Small transaction size ($76K) and routine nature suggest negligible market reaction.

Market effects

None; the filing pertains only to GE HealthCare executive holdings.

None; limited to US equity market participants.

Low; does not affect broader market dynamics.

Counterpoint

Even small insider withholdings can signal confidence in the stock, but the size here is too trivial to infer sentiment.

Key entities

  • Jeannette Bankes

    CEO, Patient Care Solutions at GE HealthCare

Related articles

$GEHCMedAI 8/10

GE HealthCare stock maintained at Buy by BTIG on imaging tech

BTIG maintained a Buy rating and $79 price target for GE HealthCare (GEHC) after positive feedback on its new photon-counting CT system. GEHC stock is down 22% YTD but is considered undervalued. The company reported Q2 revenue of $5.295B, beating estimates, and raised its price target to $85. GEHC's backlog reached $23.9B, indicating strong demand.

$GEHCMedAI 8/10

GE HealthCare (GEHC) Reportedly Eyes $1B Sofie Deal. What Would Ownership Add?

GE HealthCare (GEHC) is reportedly in talks to acquire Sofie Biosciences for $1B. Sofie holds U.S. rights to F-18 FAPI-74, a radiotracer for PET scans. GEHC already licensed global rights to Gallium-68 FAPI-46 and non-U.S. rights to F-18 FAPI-74. Sofie operates seven radiopharmacies producing F-18 FAPI-74. The deal's value depends on additional rights, manufacturing earnings, and operational benefits.

$GEHCHighAI 9/10

GE HealthCare Reportedly In Talks To Buy Sofie Biosciences For About $1 Billion

GE HealthCare is reportedly in advanced talks to acquire Sofie Biosciences for around $1 billion, according to the Financial Times. Sofie specializes in radiopharmaceuticals for PET imaging, which could expand GE HealthCare's diagnostics portfolio and create recurring revenue streams. The deal would mark GE HealthCare's second major acquisition since its 2023 separation from General Electric.

$GEHCHighAI 9/10

GE HealthCare Technologies in talks to buy Sofie Biosciences

GE HealthCare Technologies is in talks to acquire Sofie Biosciences for approximately $1 billion, according to the Financial Times. The deal, which could be announced next week, would be GE HealthCare's second major acquisition since its split from General Electric in 2024. Sofie specializes in radioactive chemicals used in cancer scans, and the acquisition would strengthen GE HealthCare's pharmaceutical diagnostics division.